Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi-Aventis Groupe
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
COMPARISON OF TWO THERAPEUTIC STRATEGIES FOR TREATING TYPE 2 DIABETIC PATIENTS POORLY CONTROLLED WITH BASAL INSULIN ASSOCIATED WITH ORAL ANTIDIABETIC DRUGS: 6-MONTH PROOF OF CONCEPT STUDY
The primary objective of the study is to evaluate the efficacy (measured by the percentage of patients achieving an Hemoglobin A1c (HbA1c) level at the end of treatment period < 7%) of a single inject...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Assessment of the early efficacy response rate of leflunomide according to the initial dosing regimen in the treatment of naïve-DMARD early RA-patients
The primary objective of this study is to assess the clinical efficacy response rate using ACR20 criteria as primary endpoint at 3-month in each initial dosing regimen group of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC RISK FACTORS
The Primary End-point is the fractional catabolic rate of ApoA-I in HDL after 12 months of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A ?Real World? Trial to determine efficacy and health outcomes of TOUJEO compared to ?standard of care? basal insulin in patients already using basal insulin. Ensayo "mundo real" para detarminar la eficacia y los resultados de salud de Toujeo® en comparación con las insulinas del tratamiento basal estándar en pacientes ya tratados con insulina basal
To demonstrate non-inferiority of Toujeo versus ?standard of care? basal insulin therapy as measured by glycated hemoglobin (HbA1c) change. Demostrar la no inferioridad de Toujeo frente a un tra...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated with Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent Καμπαζιταξέλη έναντι της αλλαγής σε εναλακτικό παράγοντα που στοχεύει στον υποδοχέα των ανδρογόνων (AR) (αμπιρατερόνη ή ενζαλουταμίδη) σε ασθενείς με μεταστατικό ευνουχοάντοχο καρκίνο του προστάτη (mCRPC) που έλαβαν στο παρελθόν θεραπεία με δοσεταξέλη και στους οποίους απέτυχε γρήγορα προηγούμενη θεραπεία με παράγοντα που στοχεύει στον AR
To compare the radiographic progression-free survival (rPFS) of chemotherapy (cabazitaxel plus prednisone, Arm A) versus AR-targeted therapy (enzalutamide or abiraterone acetate plus prednisone, Arm B...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
ENSAYO CLÍNICO RANDOMIZADO FASE II DE DOCETAXEL-CARBOPLATINO EN COMBINACIÓN CON INIPARIB (BSI-201), Y DOCETAXEL-CARBOPLATINO COMO TRATAMIENTO NEOADYUVANTE DE PACIENTES CON CÁNCER DE MAMA ESTADIO TEMPRANO Y FENOTIPO TRIPLE NEGATIVO
El objetivo principal del estudio consiste en evaluar y clasificar la actividad antitumoral, determinada por medio de la tasa de respuesta completa patológica (RCp) en la mama y en los ganglios linfát...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
TARGET GLYCEMIC CONTROL AND THE INCIDENCE OF DOCUMENTED SYMPTOMATIC HYPOGLYCEMIA IN INSULIN NAÏVE SUBJECTS WITH TYPE 2 DIABETES FAILING ON ORAL HYPOGLYCEMIC AGENT(S) AND TREATED WITH LANTUS (INSULIN GLARGINE) OR LEVEMIR (INSULIN DETEMIR): MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, COMPARATIVE, PARALLEL-GROUP STUDY
To demonstrate the non-inferiority of insulin glargine in comparison to insulin detemir in term of percentage of patients who reach the target of HbA1c < 7% at the end of the treatment period and do n...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A NON-INVASIVE EVALUATION OF BONE MICROARCHITECTURE MODIFICATION IN OSTEOPENIC POSTMENOPAUSAL WOMEN BY 3D-PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY : A 24-MONTH, MONOCENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY COMPARING WEEKLY ORAL RISEDRONATE 35 MG AND PLACEBO
The primary objective of this study is to compare risedronate 35 mg and placebo with respect to percent change at 12-month for distal radius trabecular bone volume (BV/TV) in osteopenic postmenopausa...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A 24-week, open, multicenter, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents
The primary objective of this study is to demonstrate the superiority of a strategy with insulin glargine in comparison with a strategy including the premixed insulin in term of percentage of patients...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A “Real World” Trial to determine efficacy and health outcomes of TOUJEO compared to “standard of care” basal insulins in insulin naïve patients intiating insulin
To demonstrate non-inferiority of Toujeo versus “standard of care” basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change.
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
Next